PRESS RELEASE
POSITIVE RECOMMENDATION OF THE DATA AND SAFETY MONITORING BOARD TO CONTINUE THE PHASE 2 STUDY EVALUATING ANTIVIRAL ACTIVITY OF MASITINIB IN COVID-19
Paris, 14 September 2022, 6.15pm CET
AB Science SA (Euronext – FR0010557264 – AB) right this moment introduced continuation of the Phase 2 examine evaluating the antiviral exercise of masitinib in sufferers who’ve a confirmed analysis of COVID-19, following the recommendation of the Data and Safety Monitoring Board (DSMB).
This randomized (1:1), double-blind, section 2 examine (AB21002) in 78 sufferers, is designed to judge the anti-viral efficacy of masitinib in non hospitalized sufferers who’re in danger of creating extreme COVID-19 and in hospitalized sufferers with want of oxygen (by way of face masks or nasal cannula).
The evaluation was to evaluate the security of the remedy and was based mostly on the first 50% of the affected person focused recruitment. The DSMB indicated that there was no security concern and advisable continuation of the examine with out restrictions.
This examine is concentrating on the identical inhabitants as registered antiviral therapies, particularly Paxlovid® (Pfizer) and Molnupiravir® (Merck).
AB Science at the moment has two on-going section 2 scientific research in COVID-19:
- Study AB21002, evaluating the antiviral exercise of masitinib in sufferers with symptomatic delicate to reasonable COVID-19.
- Study AB20001, evaluating the security and efficacy of masitinib plus isoquercetin in hospitalized sufferers with reasonable or extreme COVID-19.
Both research have now obtained constructive recommendation from the DSMB.
About AB Science
Founded in 2001, AB Science is a pharmaceutical firm specializing in the analysis, growth and commercialization of protein kinase inhibitors (PKIs), a category of focused proteins whose motion are key in signaling pathways inside cells. Our applications goal solely illnesses with excessive unmet medical wants, typically deadly with brief time period survival or uncommon or refractory to earlier line of remedy.
AB Science has developed a proprietary portfolio of molecules and the Company’s lead compound, masitinib, has already been registered for veterinary drugs and is developed in human drugs in oncology, neurological illnesses, inflammatory illnesses and viral illnesses. The firm is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).
Further data is on the market on AB Science’s web site:
www.ab-science.com.
Forward-looking Statements – AB Science
This press launch comprises ahead-trying statements. These statements will not be historic details. These statements embody projections and estimates in addition to the assumptions on which they’re based mostly, statements based mostly on initiatives, targets, intentions and expectations concerning monetary outcomes, occasions, operations, future companies, product growth and their potential or future efficiency.
These ahead-trying statements can typically be recognized by the phrases “expect”, “anticipate”, “believe”, “intend”, “estimate” or “plan” in addition to different comparable phrases. While AB Science believes these ahead-trying statements are affordable, buyers are cautioned that these ahead-trying statements are topic to quite a few dangers and uncertainties which might be tough to foretell and usually past the management of AB Science and which can indicate that outcomes and precise occasions considerably differ from these expressed, induced or anticipated in the ahead-trying data and statements. These dangers and uncertainties embody the uncertainties associated to product growth of the Company which is probably not profitable or to the advertising and marketing authorizations granted by competent authorities or, extra usually, any components which will have an effect on advertising and marketing capability of the merchandise developed by AB Science, in addition to these developed or recognized in the public paperwork revealed by AB Science. AB Science disclaims any obligation or enterprise to replace the ahead-trying data and statements, topic to the relevant rules, particularly articles 223-1 et seq. of the AMF General Regulations.
For extra data, please contact:
AB Science
Financial Communication & Media Relations
[email protected]
